معرفی
Lee L. Rubin, Ph.D., is a Principal Faculty member at the Harvard Stem Cell Institute (HSCI) and Co-chair of the HSCI Nervous System Disease Program. His research focuses on molecular mediators of neurodegenerative diseases, including Parkinson’s disease, ALS, and SMA, with an emphasis on developing preclinical therapeutic candidates. Rubin’s work integrates induced pluripotent stem cell technologies to model diseases and discover treatments.
Key areas of research include investigating aging-related factors such as GDF11 and their potential to improve neurodegenerative conditions. He previously discovered Tysabri (for multiple sclerosis) and hedgehog-signaling pathway modulators, one of which is now used clinically for metastatic basal cell carcinoma and stem cell differentiation.
Rubin earned his Ph.D. in Neuroscience from Rockefeller University and completed postdoctoral training at Harvard Medical School and Stanford University School of Medicine. His affiliations include Harvard Medical School, Harvard Faculty of Arts and Sciences, and collaborations with institutions like Evotec for ALS research.
Rubin’s lab (Rubin Laboratory) actively explores therapeutic strategies using patient-derived neurons and aging mechanisms. Despite no explicitly listed awards or grants in the text, his contributions to drug discovery and stem cell technologies highlight significant scientific impact.
